Subject:
- Active Substance: Maralixibat
- Name: Livmarli®
- Therapeutic area: Cholestatic pruritus
- Pharmaceutical company: Mirum Pharmaceuticals Germany GmbH
Time table:
- Start: 15.01.2023
- Publication of assessment: 17.04.2023
- End of public hearing: 08.05.2023
- Final decision by G-BA: beginning of July 2023
Comparative therapy:
- No comparative therapy due to orphan drug designation